Cao et al. therefore suggest that GSK3β is the key driving force in ovarian cancer development, the explanation being its metabolic effects, namely decreased glycogenesis and increased glucose utilization through the process of glycolysis [81]. The gene discussed is GSK3B; the disease is ovarian carcinoma.